申请人:Rigel Pharmaceuticals, Inc.
公开号:US10233170B2
公开(公告)日:2019-03-19
The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.
本文所述的发明包括式(IV)化合物和一种治疗癌症的方法,该方法包括给患有癌症的受试者施用其中一种化合物,并结合另一种癌症治疗方法。化合物(IV)抑制 TGF-β 超家族成员如 Nodal 或 Activin 的信号转导。